SGN-CD33A: Interim Phase I data

Interim data from 52 evaluable CD33-positive AML patients in an open-label, dose-escalation, U.S. Phase I trial showed IV SGN-CD33A led to complete remission or complete remission with incomplete recovery (CR/CRi) in 11 patients. Additionally, 12 patients achieved a morphologic leukemia-free state. In patients who achieved CR/CRi, median time to neutrophil count recovery was 6.7 weeks and median time to platelet count recovery was 12 weeks. Of 17 evaluable patients treated at the 40 µg/kg dose of SGN-CD33A, 5 achieved CR/CRi. Of 22 evaluable patients treated at the 40 µg/kg dose level or higher, 17 had a ³50% reduction in bone marrow blasts. ...